Journal of International Psychiatry

[Abstract] Objective: To analyze the effect of escitalopram in adjuvant treatment of patients with functional gastrointestinal diseases (FGIDs) with anxiety and depression. Methods: 117 patients with FGIDs with anxiety and depression disorder in our department from August 2018 to December 2020 were selected as the research objects, and they were divided into two groups according to the lottery method. The 58 patients in the control group were treated with mosapride combined with pinaverium bromide, and the 59 patients in the observation group were treated with escitalopram on the basis of the control group. The gastric emptying rate, negative emotions, and related gastrointestinal hormones were compared between the two groups. , Autonomic dysfunction. Results: The gastric emptying rate and gastrin level of the observation group were significantly higher than those of the control group (P<0.05); the observation group Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA) scores, motilin levels, sympathetic hyperactivity The number of hyperactive and unstable vagus nerves was lower than that of the control group (P<0.05).Conclusion: Escitalopram combined with pinaverium bromide and mosapride are effective in the treatment of patients with FGIDs with anxiety and depression, which can improve the gastrointestinal function of the patients and reduce the symptoms of depression.

Keywords: Mosapride; Pinaverium Bromide; Functional Gastrointestinal Disease; Escitalopram; Acetylcholine